The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 27, 2025
Filed:
Nov. 08, 2019
The Broad Institute, Inc., Cambridge, MA (US);
Dana-farber Cancer Institute, Inc.;
Instituto Carlos Slim DE LA Salud, A.c., Mexico City, MX;
Steven Corsello, Boston, MA (US);
Ryan Spangler, Cambridge, MA (US);
Rohith Nagari, Cambridge, MA (US);
Todd Golub, Cambridge, MA (US);
THE BROAD INSTITUTE, INC., Cambridge, MA (US);
DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US);
INSTITUTO CARLOS SLIM DE LA SALUD, A.C., Mexico City, MX;
Abstract
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers that exhibit elevated expression and/or amplification of the ABCB1 (MDR1) transporter, optionally for reasons related to development of chemotherapeutic resistance having occurred during treatment with an initial chemotherapeutic drug. In particular, the instant disclosure provides for identification of a cancer as possessing elevated ABCB1 expression and/or exhibiting resistance to a non-tepoxalin chemotherapeutic drug, and selecting and/or administering tepoxalin, a tepoxalin derivative and/or metabolite thereof as a therapeutic agent for such a cancer and/or subject having or at risk of developing such a cancer. Methods and compositions for therapies that combine such tepoxalin or tepoxalin-related compounds with other cancer therapies and/or chemotherapeutic agents are also provided.